Updated Jul 16, 2026 · Last SEC filing 2026-07-02
Maze Therapeutics, Inc. (MAZE) has filed 19 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-07-02. 4 Form 8-K material event filings were reported by MAZE in the last 90 days. 4 Form 144 notices of proposed sale were filed for MAZE stock. InsiderAlpha tracks every MAZE SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.
| SIC classification | Biological Products, (No Diagnostic Substances) (SIC 2836) |
|---|---|
| SEC CIK | 0001842295 |
| Form 4 filings (90d) | 19 |
|---|---|
| Form 8-K filings (90d) | 4 |
| Form 144 notices (90d) | 4 |
| Latest Form 4 filing | 2026-07-02 |
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Bernstein Harold | President, R&D & CMO | M — Option exercise | 14.6K | $10.42 | $152K | SEC | |
| Coloma Jason V | Chief Executive Officer | S — Open-market sale | 30.3K | $29.95 | $908K | SEC | |
| Bernstein Harold | President, R&D & CMO | S — Open-market sale | 1.2K | $30.34 | $36K | SEC | |
| Coloma Jason V | Chief Executive Officer | S — Open-market sale | 2.6K | $29.98 | $78K | SEC | |
| Bernstein Harold | President, R&D & CMO | S — Open-market sale | 13.4K | $29.86 | $400K | SEC | |
| Coloma Jason V | Chief Executive Officer | S — Open-market sale | 1.6K | $30.44 | $49K | SEC | |
| Dandekar Atul | CSBO | M — Option exercise | 7.5K | $10.42 | $78K | SEC | |
| Dandekar Atul | CSBO | S — Open-market sale | 7.5K | $28.02 | $210K | SEC | |
| Coloma Jason V | Chief Executive Officer | S — Open-market sale | 23.9K | $26.05 | $622K | SEC | |
| Coloma Jason V | Chief Executive Officer | S — Open-market sale | 2.0K | $26.00 | $51K | SEC | |
| Coloma Jason V | Chief Executive Officer | S — Open-market sale | 2.0K | $26.00 | $53K | SEC | |
| Coloma Jason V | Chief Executive Officer | S — Open-market sale | 6.1K | $26.20 | $160K | SEC | |
| Coloma Jason V | Chief Executive Officer | S — Open-market sale | 553 | $26.24 | $15K | SEC | |
| Bernstein Harold | President, R&D & CMO | M — Option exercise | 14.9K | $10.42 | $155K | SEC | |
| Bernstein Harold | President, R&D & CMO | S — Open-market sale | 1.6K | $26.36 | $42K | SEC |
All transactions sourced from SEC EDGAR Form 4 filings for Maze Therapeutics, Inc. (MAZE). Updated in real time as new filings are submitted to the SEC.
| Insider | Form 4 filings | Total transaction value |
|---|---|---|
| Coloma Jason V | 13 | $2.83M |
| Dandekar Atul | 13 | $982K |
| Bernstein Harold | 11 | $1.67M |
| HOMCY CHARLES J | 2 | — |
| Andrews Nancy C | 1 | — |
Form 144 must be filed before insiders sell restricted or control stock above SEC thresholds. A cluster of Form 144 notices often precedes a wave of insider distribution.
SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in MAZE insider filings:
| P | Open-market purchase by the insider |
|---|---|
| S | Open-market sale by the insider |
| A | Grant, award, or other acquisition from the issuer |
| M | Exercise or conversion of derivative security (e.g. options) |
| F | Payment of exercise price or tax liability via share withholding |
| G | Bona-fide gift of securities |
| D | Disposition to the issuer (e.g. share buyback participation) |
| J | Other acquisition or disposition |
| X | Exercise of in-the-money or at-the-money derivative security |
| C | Conversion of derivative security |
| V | Transaction voluntarily reported earlier than required |
Open the live MAZE dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.